董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joseph Slattery | 男 | Director | 55 | 未披露 | 未持股 | 2021-01-08 |
| Otello Stampacchia | 男 | Chief Executive Officer and Chairman of the Board of Director | 51 | 未披露 | 未持股 | 2021-01-08 |
| Jan van de Winkel | 男 | Director | 59 | 未披露 | 未持股 | 2021-01-08 |
| Michelle Doig | 女 | President and Director | 47 | 未披露 | 未持股 | 2021-01-08 |
| Martin Babler | 男 | Director | 56 | 未披露 | 未持股 | 2021-01-08 |
| Daniel S. Lynch | 男 | Director | 63 | 未披露 | 未持股 | 2021-01-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Otello Stampacchia | 男 | Chief Executive Officer and Chairman of the Board of Director | 51 | 未披露 | 未持股 | 2021-01-08 |
| Michelle Doig | 女 | President and Director | 47 | 未披露 | 未持股 | 2021-01-08 |
| Francesco Draetta | 男 | Chief Financial Officer | 36 | 未披露 | 未持股 | 2021-01-08 |
| Vincent Ossipow | 男 | Chief Scientific Officer | 52 | 未披露 | 未持股 | 2021-01-08 |
董事简历
中英对照 | 中文 | 英文- Joseph Slattery
-
Joseph Slattery，一直是Replimune Group, Inc.的成员。自2017年起担任董事会成员。此前，他于2019年3月至2020年3月31日担任Replimune Group, Inc.的首席独立董事。2013年10月至2019年12月，他担任Asensus Surgical, Inc.的执行副总裁兼首席财务官。从2010年到2013年，他担任Baxano Surgical, Inc.的执行副总裁兼首席财务官。此前，从1996年到2007年，他在Digene Corporation担任各种职务，包括从2006年到2007年担任首席财务官和财务和信息系统高级副总裁。他是Morphic Therapeutic, Inc.和CVRx Inc.的董事会成员，他曾担任Omega Alpha SPAC, Baxano Surgical, Inc.， Exosome Diagnostics, Inc.和Micromet, Inc.的董事。他持有Bentley University的会计学士学位，是一名注册会计师。
Joseph Slattery,served as Executive Vice President and Chief Financial Officer of Asensus Surgical, Inc. from October 2013 through December 2019. From 2010 to 2013, Mr. Slattery served as Executive Vice President and Chief Financial Officer at Baxano Surgical, Inc. Previously, from 1996 to 2007, Mr. Slattery served in various roles of increasing responsibility at Digene Corporation, including as Chief Financial Officer and Senior Vice President of Finance and Information Systems from 2006 to 2007. Mr. Slattery currently serves on the board of directors of CVRx Inc. since October 2008. Previously, he served as a director of Morphic Therapeutic, Inc., Omega Alpha SPAC, Baxano Surgical, Inc., Exosome Diagnostics, Inc. and Micromet, Inc. Mr. Slattery received a B.S. in Accounting from Bentley University and is a certified public accountant. - Joseph Slattery，一直是Replimune Group, Inc.的成员。自2017年起担任董事会成员。此前，他于2019年3月至2020年3月31日担任Replimune Group, Inc.的首席独立董事。2013年10月至2019年12月，他担任Asensus Surgical, Inc.的执行副总裁兼首席财务官。从2010年到2013年，他担任Baxano Surgical, Inc.的执行副总裁兼首席财务官。此前，从1996年到2007年，他在Digene Corporation担任各种职务，包括从2006年到2007年担任首席财务官和财务和信息系统高级副总裁。他是Morphic Therapeutic, Inc.和CVRx Inc.的董事会成员，他曾担任Omega Alpha SPAC, Baxano Surgical, Inc.， Exosome Diagnostics, Inc.和Micromet, Inc.的董事。他持有Bentley University的会计学士学位，是一名注册会计师。
- Joseph Slattery,served as Executive Vice President and Chief Financial Officer of Asensus Surgical, Inc. from October 2013 through December 2019. From 2010 to 2013, Mr. Slattery served as Executive Vice President and Chief Financial Officer at Baxano Surgical, Inc. Previously, from 1996 to 2007, Mr. Slattery served in various roles of increasing responsibility at Digene Corporation, including as Chief Financial Officer and Senior Vice President of Finance and Information Systems from 2006 to 2007. Mr. Slattery currently serves on the board of directors of CVRx Inc. since October 2008. Previously, he served as a director of Morphic Therapeutic, Inc., Omega Alpha SPAC, Baxano Surgical, Inc., Exosome Diagnostics, Inc. and Micromet, Inc. Mr. Slattery received a B.S. in Accounting from Bentley University and is a certified public accountant.
- Otello Stampacchia
-
Otello Stampacchia自2020年12月以来一直担任我们的董事会成员。Stampacchia博士是Omega Funds的创始人、董事总经理和投资委员会成员。Stampacchia博士目前在KronosBio，Inc.公司董事会任职。纳斯达克市场代码:KRON、MorphicHolding，Inc.（纳斯达克市场代码:MORF）和ReplimuneGroup，Inc.（纳斯达克市场代码:REPL），以及私营公司:Amunix Pharmaceuticals，Inc.和Scorpion Therapeutics，Inc.。在2004年1月创立Omega之前，Stampacchia博士是Alpinvest Partners（现在是凯雷集团的一部分）的合伙人。任职Alpinvest Partners公司之前，他曾担任Lombard Odier Immunology Fund（投资工具，位于瑞士日内瓦，投资于世界各地的公共和私营梦百合公司）的投资组合经理。此前，Stampacchia博士是高盛（Goldman Sachs）梦百合企业融资与并购团队的成员。在高盛之前，他帮助联合创立了Index Securities（现在的Index Ventures）梦百合投资活动。Stampacchia博士在帕维亚大学（University of Pavia）获得植物遗传学理学硕士学位，在日内瓦大学（University of Geneva）获得分子生物学理学硕士学位和分子生物学哲学博士学位，在欧洲联盟斯特拉斯堡（European Union Strasbourg）获得生物技术哲学博士学位。
Otello Stampacchia has served as a member of Board since July 2025. Dr. Stampacchia previoly served on the board of directors of Ikena from December 2020 to July 2025. Dr. Stampacchia is founder, managing director and member of the investment committee at Omega Fund Management, LLC. Dr. Stampacchia currently serves on the boards of directors of several private companies. Dr. Stampacchia previoly served on the board of directors of Kronos Bio, Inc. (Nasdaq: KRON), Median Technologies, Inc., Nuvation Bio, Inc. (NYSE: NUVB) and Replimune Group, Inc. (Nasdaq: REPL). Prior to founding Omega in January 2004, Dr. Stampacchia was a Partner at AlpInvest Partners (now part of The Carlyle Group). Before AlpInvest Partners, he was the portfolio manager of the Lombard Odier Immunology Fund, an investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previoly, Dr. Stampacchia was a member of the HealthCare corporate finance and M&A team at Goldman Sachs. Before Goldman Sachs, he helped co found the healthcare investment activities at Index Securities (now Index Ventures). Dr. Stampacchia received a Masters of Science in Plant Genetics from the University of Pavia, a Masters of Science in Molecular Biology, a Doctorate of Philosophy in Molecular Biology from the University of Geneva and a Doctorate of Philosophy in Biotechnology from European Union Strasbg. - Otello Stampacchia自2020年12月以来一直担任我们的董事会成员。Stampacchia博士是Omega Funds的创始人、董事总经理和投资委员会成员。Stampacchia博士目前在KronosBio，Inc.公司董事会任职。纳斯达克市场代码:KRON、MorphicHolding，Inc.（纳斯达克市场代码:MORF）和ReplimuneGroup，Inc.（纳斯达克市场代码:REPL），以及私营公司:Amunix Pharmaceuticals，Inc.和Scorpion Therapeutics，Inc.。在2004年1月创立Omega之前，Stampacchia博士是Alpinvest Partners（现在是凯雷集团的一部分）的合伙人。任职Alpinvest Partners公司之前，他曾担任Lombard Odier Immunology Fund（投资工具，位于瑞士日内瓦，投资于世界各地的公共和私营梦百合公司）的投资组合经理。此前，Stampacchia博士是高盛（Goldman Sachs）梦百合企业融资与并购团队的成员。在高盛之前，他帮助联合创立了Index Securities（现在的Index Ventures）梦百合投资活动。Stampacchia博士在帕维亚大学（University of Pavia）获得植物遗传学理学硕士学位，在日内瓦大学（University of Geneva）获得分子生物学理学硕士学位和分子生物学哲学博士学位，在欧洲联盟斯特拉斯堡（European Union Strasbourg）获得生物技术哲学博士学位。
- Otello Stampacchia has served as a member of Board since July 2025. Dr. Stampacchia previoly served on the board of directors of Ikena from December 2020 to July 2025. Dr. Stampacchia is founder, managing director and member of the investment committee at Omega Fund Management, LLC. Dr. Stampacchia currently serves on the boards of directors of several private companies. Dr. Stampacchia previoly served on the board of directors of Kronos Bio, Inc. (Nasdaq: KRON), Median Technologies, Inc., Nuvation Bio, Inc. (NYSE: NUVB) and Replimune Group, Inc. (Nasdaq: REPL). Prior to founding Omega in January 2004, Dr. Stampacchia was a Partner at AlpInvest Partners (now part of The Carlyle Group). Before AlpInvest Partners, he was the portfolio manager of the Lombard Odier Immunology Fund, an investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previoly, Dr. Stampacchia was a member of the HealthCare corporate finance and M&A team at Goldman Sachs. Before Goldman Sachs, he helped co found the healthcare investment activities at Index Securities (now Index Ventures). Dr. Stampacchia received a Masters of Science in Plant Genetics from the University of Pavia, a Masters of Science in Molecular Biology, a Doctorate of Philosophy in Molecular Biology from the University of Geneva and a Doctorate of Philosophy in Biotechnology from European Union Strasbg.
- Jan van de Winkel
-
Jan van de Winkel是我们的董事会成员。Van de Winkel博士是Genmab的联合创始人，并担任该公司的研发总裁兼首席科学官，直到2010年被任命为总裁兼首席执行官。他是超过300个科学出版物的作者，并负责超过150个专利和未决专利申请。Van de Winkel博士拥有乌得勒支大学（Utrecht University）免疫疗法教授职位。他是Hookipa Pharma Inc.的董事会主席和利欧股份Pharma A/S的董事会成员，自2017年以来一直担任这两个职位。Van de Winkel博士此前曾担任Forward PharmaA/S董事会成员，直至2017年5月。他持有the University of Nijmegen的硕士学位和博士学位。
Jan van de Winkel serves on our board of directors. Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. He is the author of over 300 scientific publications and has been responsible for over 150 patents and pending patent applications. Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University. He is chairman of the board of directors of Hookipa Pharma Inc, and member of the board of directors of Leo Pharma A/S, both roles which he has held since 2017. Dr. van de Winkel previously served as a member of the board of directors of Forward Pharma A/S until May 2017. He holds M.S. and Ph.D. degrees from the University of Nijmegen. - Jan van de Winkel是我们的董事会成员。Van de Winkel博士是Genmab的联合创始人，并担任该公司的研发总裁兼首席科学官，直到2010年被任命为总裁兼首席执行官。他是超过300个科学出版物的作者，并负责超过150个专利和未决专利申请。Van de Winkel博士拥有乌得勒支大学（Utrecht University）免疫疗法教授职位。他是Hookipa Pharma Inc.的董事会主席和利欧股份Pharma A/S的董事会成员，自2017年以来一直担任这两个职位。Van de Winkel博士此前曾担任Forward PharmaA/S董事会成员，直至2017年5月。他持有the University of Nijmegen的硕士学位和博士学位。
- Jan van de Winkel serves on our board of directors. Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. He is the author of over 300 scientific publications and has been responsible for over 150 patents and pending patent applications. Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University. He is chairman of the board of directors of Hookipa Pharma Inc, and member of the board of directors of Leo Pharma A/S, both roles which he has held since 2017. Dr. van de Winkel previously served as a member of the board of directors of Forward Pharma A/S until May 2017. He holds M.S. and Ph.D. degrees from the University of Nijmegen.
- Michelle Doig
-
Michelle Doig担任我们的总裁和我们董事会的董事。自2016年12月起，Doig女士一直担任Omega的合伙人。Doig女士目前自2019年6月起还担任Nuvation Bio的董事会成员。任职Omega公司之前，她曾担任Third Rock Ventures公司的公司财务董事（从2013年11月到2016年12月），在那里她曾支持众多投资组合公司的融资战略和执行。加入Third Rock Ventures公司之前，Doig女士曾担任Abingworth公司（位于伦敦和波士顿办事处）的公司财务负责人。她还是伦敦雷曼兄弟国际公司、纽约JP摩根/H&；Q以及多伦多和纽约摩根士丹利的生命科学投资银行家。Doig女士以优异成绩毕业于伦敦西安大略大学艾维商学院（Ivey School of Business at the University of Western Ontario）的工商管理学位。
Michelle Doig,has served as a director of Artios Pharma Ltd, since July 2021 and previously, she served on the boards of directors of Nuvation Bio Inc. (NYSE: NUVB) from July 2019 to June 2021 and Omega Alpha SPAC (Nasdaq: OMEG) from November 2020 to January 2023. Since December 2016, Ms. Doig has been a Partner and the Head of Corporate Development at Omega Funds. Prior to that, she was Director of Corporate Finance at Third Rock Ventures from December 2013 to December 2016. From 2004 to 2013, she was a Principal at Abingworth. Ms. Doig has also worked as a life sciences investment banker with Lehman Brothers International (London), J.P. Morgan (New York), and Morgan Stanley Canada (Toronto). She received a degree in Business Administration from the Richard Ivey School of Business at the University of Western Ontario. - Michelle Doig担任我们的总裁和我们董事会的董事。自2016年12月起，Doig女士一直担任Omega的合伙人。Doig女士目前自2019年6月起还担任Nuvation Bio的董事会成员。任职Omega公司之前，她曾担任Third Rock Ventures公司的公司财务董事（从2013年11月到2016年12月），在那里她曾支持众多投资组合公司的融资战略和执行。加入Third Rock Ventures公司之前，Doig女士曾担任Abingworth公司（位于伦敦和波士顿办事处）的公司财务负责人。她还是伦敦雷曼兄弟国际公司、纽约JP摩根/H&；Q以及多伦多和纽约摩根士丹利的生命科学投资银行家。Doig女士以优异成绩毕业于伦敦西安大略大学艾维商学院（Ivey School of Business at the University of Western Ontario）的工商管理学位。
- Michelle Doig,has served as a director of Artios Pharma Ltd, since July 2021 and previously, she served on the boards of directors of Nuvation Bio Inc. (NYSE: NUVB) from July 2019 to June 2021 and Omega Alpha SPAC (Nasdaq: OMEG) from November 2020 to January 2023. Since December 2016, Ms. Doig has been a Partner and the Head of Corporate Development at Omega Funds. Prior to that, she was Director of Corporate Finance at Third Rock Ventures from December 2013 to December 2016. From 2004 to 2013, she was a Principal at Abingworth. Ms. Doig has also worked as a life sciences investment banker with Lehman Brothers International (London), J.P. Morgan (New York), and Morgan Stanley Canada (Toronto). She received a degree in Business Administration from the Richard Ivey School of Business at the University of Western Ontario.
- Martin Babler
-
Martin Babler，2008年5月以来，他担任Infinity Pharmaceuticals, Inc.的董事会的成员。2011年4月以来，他成为Principia BioPharma, Inc.（一个刚刚起步的公司，开发自身免疫性疾病的新药物）的首席执行官和董事。从2008年2月到2011年4月，他担任 Talima Therapeutics, Inc.（云网络公司）的首席执行官。加入Talima之前的2000年到2006年，他曾是基因泰克（Genentech）（一个上市的生物制药公司）免疫学销售和营销和心血管市场营销董事。加入基因泰克（Genentech）之前，他担任Eli Lilly and Compan的各种销售、销售管理、营销和业务拓展的职务，并不断被提拔。他获得瑞士联邦理工学院（ the Swiss Federal Institute of Technology）的药剂学/药物学学位并进入凯洛格管理研究所（ Kellogg Graduate School of Management）进行主管发展项目（Executive Development Program ）学习。
Martin Babler,has served as Alumis Inc. President, Chief Executive, and chairman of Alumis Inc. board of directors since September 2021. From April 2011 until November 2020, he served as President and Chief Executive Officer at Principia Biopharma Inc., a biotechnology company acquired by Sanofi S.A. in September 2020. From December 2007 to April 2011, Mr. Babler served as President and Chief Executive Officer of Talima Therapeutics, Inc., a pharmaceutical company. From 1998 to 2007, Mr. Babler held several positions at Genentech, Inc., a biopharmaceutical company, most notably as Vice President, Immunology Sales and Marketing. Mr. Babler presently serves on the board of directors of Prelude Therapeutics Inc., a biopharmaceutical company, and Sardona Therapeutics, Inc. Mr. Babler received a Swiss Federal Diploma in pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University. - Martin Babler，2008年5月以来，他担任Infinity Pharmaceuticals, Inc.的董事会的成员。2011年4月以来，他成为Principia BioPharma, Inc.（一个刚刚起步的公司，开发自身免疫性疾病的新药物）的首席执行官和董事。从2008年2月到2011年4月，他担任 Talima Therapeutics, Inc.（云网络公司）的首席执行官。加入Talima之前的2000年到2006年，他曾是基因泰克（Genentech）（一个上市的生物制药公司）免疫学销售和营销和心血管市场营销董事。加入基因泰克（Genentech）之前，他担任Eli Lilly and Compan的各种销售、销售管理、营销和业务拓展的职务，并不断被提拔。他获得瑞士联邦理工学院（ the Swiss Federal Institute of Technology）的药剂学/药物学学位并进入凯洛格管理研究所（ Kellogg Graduate School of Management）进行主管发展项目（Executive Development Program ）学习。
- Martin Babler,has served as Alumis Inc. President, Chief Executive, and chairman of Alumis Inc. board of directors since September 2021. From April 2011 until November 2020, he served as President and Chief Executive Officer at Principia Biopharma Inc., a biotechnology company acquired by Sanofi S.A. in September 2020. From December 2007 to April 2011, Mr. Babler served as President and Chief Executive Officer of Talima Therapeutics, Inc., a pharmaceutical company. From 1998 to 2007, Mr. Babler held several positions at Genentech, Inc., a biopharmaceutical company, most notably as Vice President, Immunology Sales and Marketing. Mr. Babler presently serves on the board of directors of Prelude Therapeutics Inc., a biopharmaceutical company, and Sardona Therapeutics, Inc. Mr. Babler received a Swiss Federal Diploma in pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University.
- Daniel S. Lynch
-
Daniel S. Lynch，现为Xilio Therapeutics, Inc.的董事；2012年10月担任Omega Alpha SPAC的董事会主席。从2011年5月起，担任董事长，当时他加入Third Rock Ventures, L.P.，成为入驻企业家。2007年10月以来，他为多家私营的生物制药公司提供咨询服务、担任行政职务或董事，包括：Stromedix, Inc，直到2012年2月它被Biogen Idec收购； Avila Therapeutics, Inc. ，直到2012年2月，它被Celgene Corporation收购；BIND Biosciences, Inc；Eleven Biotherapeutics；RaNA Therapeutics；Nimbus Discovery, LLC；Edimer Pharmaceuticals；Ember Therapeutics；Blueprint Medicines。之前，他是ImClone Systems Corporation的首席执行官、首席财务官。作为首席执行官，他领导了该公司的成功转型，重塑辉煌，并确保了癌症新药ERBITUX （Cetuximab）通过FDA的审批；作为首席财务官，他领导了ImClone 、Bristol-Myers Squibb成立大型合资企业的谈判工作。职业生涯早期，他在Bristol-Myers Squibb工作了15年，担任过各种财务职位。他在U.S. Oncology担任了5年的董事、审核委员会成员，直到2010年12月它被McKesson收购。他在Wesleyan University获得数学学士学位，在Darden Graduate School of Business Administration at the University of Virginia获得工商管理硕士学位。
Daniel S. Lynch,has served as a member of 2seventy Bio, Inc. Board of Directors since October 15, 2021. Prior to the separation by bluebird bio of its oncology portfolio and programs into 2seventy bio, which 2seventy Bio, Inc. refer to as the separation, Mr. Lynch served on the Board of Directors of bluebird bio. Mr. Lynch joined Google Ventures in 2021 as Executive Venture Partner and partners with life sciences CEOs and executives as a trusted advisor. As a coach and investor, he places deep emphasis on long-term relationships. Since 2007, Mr. Lynch has advised and served as an executive chair or member of the boards for multiple biopharmaceutical companies, including Stromedix (acquired by Biogen), Avila Therapeutics (acquired by Celgene Corporation), Nimbus Discovery, Edimer Pharmaceuticals, Ember Therapeutics, Proclara Biosciences, Surface Oncology, Sesen Bio (formerly Eleven Biotherapeutics), Xilio Therapeutics, eGenesis Bio, BIND Biosciences, and Blueprint Medicines. Mr. Lynch currently serves on the board of SpringWorks Therapeutics. He also served as an entrepreneur in residence and venture partner at Third Rock Ventures and was a senior advisor at the firm until 2021. Previously, Mr. Lynch served as CEO and CFO of ImClone Systems Corporation. As CEO, he led the company through a significant turnaround, helping to restore its reputation and secure FDA approval of the novel cancer treatment ERBITUX (Cetuximab). As CFO, Mr. Lynch led negotiations to form a major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he held several financial positions at Bristol-Myers Squibb for over 15 years. For five years, he served on the board of directors and the audit committee at U.S. Oncology, Inc. until its acquisition by McKesson in 2010. Mr. Lynch received his B.A. in mathematics from Wesleyan University and his M.B.A. from the Darden Graduate School of Business Administration at The University of Virginia. - Daniel S. Lynch，现为Xilio Therapeutics, Inc.的董事；2012年10月担任Omega Alpha SPAC的董事会主席。从2011年5月起，担任董事长，当时他加入Third Rock Ventures, L.P.，成为入驻企业家。2007年10月以来，他为多家私营的生物制药公司提供咨询服务、担任行政职务或董事，包括：Stromedix, Inc，直到2012年2月它被Biogen Idec收购； Avila Therapeutics, Inc. ，直到2012年2月，它被Celgene Corporation收购；BIND Biosciences, Inc；Eleven Biotherapeutics；RaNA Therapeutics；Nimbus Discovery, LLC；Edimer Pharmaceuticals；Ember Therapeutics；Blueprint Medicines。之前，他是ImClone Systems Corporation的首席执行官、首席财务官。作为首席执行官，他领导了该公司的成功转型，重塑辉煌，并确保了癌症新药ERBITUX （Cetuximab）通过FDA的审批；作为首席财务官，他领导了ImClone 、Bristol-Myers Squibb成立大型合资企业的谈判工作。职业生涯早期，他在Bristol-Myers Squibb工作了15年，担任过各种财务职位。他在U.S. Oncology担任了5年的董事、审核委员会成员，直到2010年12月它被McKesson收购。他在Wesleyan University获得数学学士学位，在Darden Graduate School of Business Administration at the University of Virginia获得工商管理硕士学位。
- Daniel S. Lynch,has served as a member of 2seventy Bio, Inc. Board of Directors since October 15, 2021. Prior to the separation by bluebird bio of its oncology portfolio and programs into 2seventy bio, which 2seventy Bio, Inc. refer to as the separation, Mr. Lynch served on the Board of Directors of bluebird bio. Mr. Lynch joined Google Ventures in 2021 as Executive Venture Partner and partners with life sciences CEOs and executives as a trusted advisor. As a coach and investor, he places deep emphasis on long-term relationships. Since 2007, Mr. Lynch has advised and served as an executive chair or member of the boards for multiple biopharmaceutical companies, including Stromedix (acquired by Biogen), Avila Therapeutics (acquired by Celgene Corporation), Nimbus Discovery, Edimer Pharmaceuticals, Ember Therapeutics, Proclara Biosciences, Surface Oncology, Sesen Bio (formerly Eleven Biotherapeutics), Xilio Therapeutics, eGenesis Bio, BIND Biosciences, and Blueprint Medicines. Mr. Lynch currently serves on the board of SpringWorks Therapeutics. He also served as an entrepreneur in residence and venture partner at Third Rock Ventures and was a senior advisor at the firm until 2021. Previously, Mr. Lynch served as CEO and CFO of ImClone Systems Corporation. As CEO, he led the company through a significant turnaround, helping to restore its reputation and secure FDA approval of the novel cancer treatment ERBITUX (Cetuximab). As CFO, Mr. Lynch led negotiations to form a major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he held several financial positions at Bristol-Myers Squibb for over 15 years. For five years, he served on the board of directors and the audit committee at U.S. Oncology, Inc. until its acquisition by McKesson in 2010. Mr. Lynch received his B.A. in mathematics from Wesleyan University and his M.B.A. from the Darden Graduate School of Business Administration at The University of Virginia.
高管简历
中英对照 | 中文 | 英文- Otello Stampacchia
Otello Stampacchia自2020年12月以来一直担任我们的董事会成员。Stampacchia博士是Omega Funds的创始人、董事总经理和投资委员会成员。Stampacchia博士目前在KronosBio，Inc.公司董事会任职。纳斯达克市场代码:KRON、MorphicHolding，Inc.（纳斯达克市场代码:MORF）和ReplimuneGroup，Inc.（纳斯达克市场代码:REPL），以及私营公司:Amunix Pharmaceuticals，Inc.和Scorpion Therapeutics，Inc.。在2004年1月创立Omega之前，Stampacchia博士是Alpinvest Partners（现在是凯雷集团的一部分）的合伙人。任职Alpinvest Partners公司之前，他曾担任Lombard Odier Immunology Fund（投资工具，位于瑞士日内瓦，投资于世界各地的公共和私营梦百合公司）的投资组合经理。此前，Stampacchia博士是高盛（Goldman Sachs）梦百合企业融资与并购团队的成员。在高盛之前，他帮助联合创立了Index Securities（现在的Index Ventures）梦百合投资活动。Stampacchia博士在帕维亚大学（University of Pavia）获得植物遗传学理学硕士学位，在日内瓦大学（University of Geneva）获得分子生物学理学硕士学位和分子生物学哲学博士学位，在欧洲联盟斯特拉斯堡（European Union Strasbourg）获得生物技术哲学博士学位。
Otello Stampacchia has served as a member of Board since July 2025. Dr. Stampacchia previoly served on the board of directors of Ikena from December 2020 to July 2025. Dr. Stampacchia is founder, managing director and member of the investment committee at Omega Fund Management, LLC. Dr. Stampacchia currently serves on the boards of directors of several private companies. Dr. Stampacchia previoly served on the board of directors of Kronos Bio, Inc. (Nasdaq: KRON), Median Technologies, Inc., Nuvation Bio, Inc. (NYSE: NUVB) and Replimune Group, Inc. (Nasdaq: REPL). Prior to founding Omega in January 2004, Dr. Stampacchia was a Partner at AlpInvest Partners (now part of The Carlyle Group). Before AlpInvest Partners, he was the portfolio manager of the Lombard Odier Immunology Fund, an investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previoly, Dr. Stampacchia was a member of the HealthCare corporate finance and M&A team at Goldman Sachs. Before Goldman Sachs, he helped co found the healthcare investment activities at Index Securities (now Index Ventures). Dr. Stampacchia received a Masters of Science in Plant Genetics from the University of Pavia, a Masters of Science in Molecular Biology, a Doctorate of Philosophy in Molecular Biology from the University of Geneva and a Doctorate of Philosophy in Biotechnology from European Union Strasbg.- Otello Stampacchia自2020年12月以来一直担任我们的董事会成员。Stampacchia博士是Omega Funds的创始人、董事总经理和投资委员会成员。Stampacchia博士目前在KronosBio，Inc.公司董事会任职。纳斯达克市场代码:KRON、MorphicHolding，Inc.（纳斯达克市场代码:MORF）和ReplimuneGroup，Inc.（纳斯达克市场代码:REPL），以及私营公司:Amunix Pharmaceuticals，Inc.和Scorpion Therapeutics，Inc.。在2004年1月创立Omega之前，Stampacchia博士是Alpinvest Partners（现在是凯雷集团的一部分）的合伙人。任职Alpinvest Partners公司之前，他曾担任Lombard Odier Immunology Fund（投资工具，位于瑞士日内瓦，投资于世界各地的公共和私营梦百合公司）的投资组合经理。此前，Stampacchia博士是高盛（Goldman Sachs）梦百合企业融资与并购团队的成员。在高盛之前，他帮助联合创立了Index Securities（现在的Index Ventures）梦百合投资活动。Stampacchia博士在帕维亚大学（University of Pavia）获得植物遗传学理学硕士学位，在日内瓦大学（University of Geneva）获得分子生物学理学硕士学位和分子生物学哲学博士学位，在欧洲联盟斯特拉斯堡（European Union Strasbourg）获得生物技术哲学博士学位。
- Otello Stampacchia has served as a member of Board since July 2025. Dr. Stampacchia previoly served on the board of directors of Ikena from December 2020 to July 2025. Dr. Stampacchia is founder, managing director and member of the investment committee at Omega Fund Management, LLC. Dr. Stampacchia currently serves on the boards of directors of several private companies. Dr. Stampacchia previoly served on the board of directors of Kronos Bio, Inc. (Nasdaq: KRON), Median Technologies, Inc., Nuvation Bio, Inc. (NYSE: NUVB) and Replimune Group, Inc. (Nasdaq: REPL). Prior to founding Omega in January 2004, Dr. Stampacchia was a Partner at AlpInvest Partners (now part of The Carlyle Group). Before AlpInvest Partners, he was the portfolio manager of the Lombard Odier Immunology Fund, an investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previoly, Dr. Stampacchia was a member of the HealthCare corporate finance and M&A team at Goldman Sachs. Before Goldman Sachs, he helped co found the healthcare investment activities at Index Securities (now Index Ventures). Dr. Stampacchia received a Masters of Science in Plant Genetics from the University of Pavia, a Masters of Science in Molecular Biology, a Doctorate of Philosophy in Molecular Biology from the University of Geneva and a Doctorate of Philosophy in Biotechnology from European Union Strasbg.
- Michelle Doig
Michelle Doig担任我们的总裁和我们董事会的董事。自2016年12月起，Doig女士一直担任Omega的合伙人。Doig女士目前自2019年6月起还担任Nuvation Bio的董事会成员。任职Omega公司之前，她曾担任Third Rock Ventures公司的公司财务董事（从2013年11月到2016年12月），在那里她曾支持众多投资组合公司的融资战略和执行。加入Third Rock Ventures公司之前，Doig女士曾担任Abingworth公司（位于伦敦和波士顿办事处）的公司财务负责人。她还是伦敦雷曼兄弟国际公司、纽约JP摩根/H&；Q以及多伦多和纽约摩根士丹利的生命科学投资银行家。Doig女士以优异成绩毕业于伦敦西安大略大学艾维商学院（Ivey School of Business at the University of Western Ontario）的工商管理学位。
Michelle Doig,has served as a director of Artios Pharma Ltd, since July 2021 and previously, she served on the boards of directors of Nuvation Bio Inc. (NYSE: NUVB) from July 2019 to June 2021 and Omega Alpha SPAC (Nasdaq: OMEG) from November 2020 to January 2023. Since December 2016, Ms. Doig has been a Partner and the Head of Corporate Development at Omega Funds. Prior to that, she was Director of Corporate Finance at Third Rock Ventures from December 2013 to December 2016. From 2004 to 2013, she was a Principal at Abingworth. Ms. Doig has also worked as a life sciences investment banker with Lehman Brothers International (London), J.P. Morgan (New York), and Morgan Stanley Canada (Toronto). She received a degree in Business Administration from the Richard Ivey School of Business at the University of Western Ontario.- Michelle Doig担任我们的总裁和我们董事会的董事。自2016年12月起，Doig女士一直担任Omega的合伙人。Doig女士目前自2019年6月起还担任Nuvation Bio的董事会成员。任职Omega公司之前，她曾担任Third Rock Ventures公司的公司财务董事（从2013年11月到2016年12月），在那里她曾支持众多投资组合公司的融资战略和执行。加入Third Rock Ventures公司之前，Doig女士曾担任Abingworth公司（位于伦敦和波士顿办事处）的公司财务负责人。她还是伦敦雷曼兄弟国际公司、纽约JP摩根/H&；Q以及多伦多和纽约摩根士丹利的生命科学投资银行家。Doig女士以优异成绩毕业于伦敦西安大略大学艾维商学院（Ivey School of Business at the University of Western Ontario）的工商管理学位。
- Michelle Doig,has served as a director of Artios Pharma Ltd, since July 2021 and previously, she served on the boards of directors of Nuvation Bio Inc. (NYSE: NUVB) from July 2019 to June 2021 and Omega Alpha SPAC (Nasdaq: OMEG) from November 2020 to January 2023. Since December 2016, Ms. Doig has been a Partner and the Head of Corporate Development at Omega Funds. Prior to that, she was Director of Corporate Finance at Third Rock Ventures from December 2013 to December 2016. From 2004 to 2013, she was a Principal at Abingworth. Ms. Doig has also worked as a life sciences investment banker with Lehman Brothers International (London), J.P. Morgan (New York), and Morgan Stanley Canada (Toronto). She received a degree in Business Administration from the Richard Ivey School of Business at the University of Western Ontario.
- Francesco Draetta
Francesco Draetta是我们的首席财务官自2016年8月起，Draetta先生一直担任Omega的合伙人。Draetta先生目前自2020年10月起担任私人公司Chord Therapeutics SA的董事会成员。加入Omega公司之前，他曾担任Brookside Mezzanine Partners公司（夹层基金，投资于美国中小型公司的次级债务和少数股权）的分析师（2015年8月至2016年8月），在那里他曾专注于尽职调查、交易管理和投资者关系。任职Brookside Mezzanine Partners公司之前，他曾担任CommonFund Capital公司（CommonFund的私人资本部门）的合伙人，在那里他曾专注于CCI公司的私人股本、风险资本和自然资源计划的尽职调查、经理选择、投资管理和投资者关系。他的职业生涯始于任职Omega公司，担任分析师。Draetta先生以优异成绩毕业于马萨诸塞大学阿默斯特分校（University of Massachusetts Amherst）的艾森伯格管理学院（Isenberg School of Management），获得金融和运营管理学士学位。他也是CFA Charterholder、CAIA Charterholder、认证FRM。
Francesco Draetta serves as our Chief Financial Officer. Since August 2016 Mr. Draetta has been a Partner at Omega. Mr. Draetta currently serves on the board of directors of private company Chord Therapeutics SA since October 2020. Prior to joining Omega, from August 2015 to August 2016 Mr. Draetta was an Analyst at Brookside Mezzanine Partners, a mezzanine fund investing in subordinated debt and minority equity in small- to mid-size companies throughout the U.S., where he focused on due diligence, deal management, and investor relations. Prior to Brookside Mezzanine Partners, Mr. Draetta was an Associate at Commonfund Capital (CCI), the private capital arm of Commonfund, where he focused on due diligence, manager selection, investment management, and investor relations for CCI’s private equity, venture capital, and natural resources programs. He began his career at Omega as an Analyst. Mr. Draetta graduated cum laude from the Isenberg School of Management at the University of Massachusetts Amherst with a BBA in Finance and Operations Management. He is also a CFA charterholder, a CAIA charterholder, and a Certified FRM.- Francesco Draetta是我们的首席财务官自2016年8月起，Draetta先生一直担任Omega的合伙人。Draetta先生目前自2020年10月起担任私人公司Chord Therapeutics SA的董事会成员。加入Omega公司之前，他曾担任Brookside Mezzanine Partners公司（夹层基金，投资于美国中小型公司的次级债务和少数股权）的分析师（2015年8月至2016年8月），在那里他曾专注于尽职调查、交易管理和投资者关系。任职Brookside Mezzanine Partners公司之前，他曾担任CommonFund Capital公司（CommonFund的私人资本部门）的合伙人，在那里他曾专注于CCI公司的私人股本、风险资本和自然资源计划的尽职调查、经理选择、投资管理和投资者关系。他的职业生涯始于任职Omega公司，担任分析师。Draetta先生以优异成绩毕业于马萨诸塞大学阿默斯特分校（University of Massachusetts Amherst）的艾森伯格管理学院（Isenberg School of Management），获得金融和运营管理学士学位。他也是CFA Charterholder、CAIA Charterholder、认证FRM。
- Francesco Draetta serves as our Chief Financial Officer. Since August 2016 Mr. Draetta has been a Partner at Omega. Mr. Draetta currently serves on the board of directors of private company Chord Therapeutics SA since October 2020. Prior to joining Omega, from August 2015 to August 2016 Mr. Draetta was an Analyst at Brookside Mezzanine Partners, a mezzanine fund investing in subordinated debt and minority equity in small- to mid-size companies throughout the U.S., where he focused on due diligence, deal management, and investor relations. Prior to Brookside Mezzanine Partners, Mr. Draetta was an Associate at Commonfund Capital (CCI), the private capital arm of Commonfund, where he focused on due diligence, manager selection, investment management, and investor relations for CCI’s private equity, venture capital, and natural resources programs. He began his career at Omega as an Analyst. Mr. Draetta graduated cum laude from the Isenberg School of Management at the University of Massachusetts Amherst with a BBA in Finance and Operations Management. He is also a CFA charterholder, a CAIA charterholder, and a Certified FRM.
- Vincent Ossipow
Vincent Ossipow自2014年6月起担任董事会成员。Ossipow博士一直是欧米茄基金的合伙人。Ossipow博士自2021年1月起还担任Omega Alpha SPAC的首席科学官。在此之前，Ossipow博士曾在部门资产管理公司和Pictet Bank担任多个投资管理职位。除了我们的董事会，Ossipow博士还任职于Immunic，Inc.，BioInvent International AB，Forx SA和Etherna Immunotherapies NV的董事会，此前曾任职于Andrew Alliance S.A.，Lifespan，Inc.，Raindance Technologies，CNX SA和Kuros Biosciences AG的董事会。Ossipow博士拥有日内瓦大学分子生物学博士学位。
Vincent Ossipow, has served as a member of our board of directors since June 2014. Dr. Ossipow has been a partner at Omega Funds. Dr. Ossipow has also served as the Chief Scientific Officer of Omega Alpha SPAC. Prior to that, Dr. Ossipow held various investment management positions at Sectoral Asset Management and Pictet Bank. In addition to our board of directors, Dr. Ossipow serves on the board of directors of Immunic, Inc., BioInvent International AB, FoRx SA, SwissThera SA, and eTheRNA immunotherapies NV, and previously served on the board of directors of Andrew Alliance S.A., Lifespan, Inc., Raindance Technologies, CNx SA and Kuros Biosciences AG. Dr. Ossipow holds a Ph.D. in molecular biology from the University of Geneva.- Vincent Ossipow自2014年6月起担任董事会成员。Ossipow博士一直是欧米茄基金的合伙人。Ossipow博士自2021年1月起还担任Omega Alpha SPAC的首席科学官。在此之前，Ossipow博士曾在部门资产管理公司和Pictet Bank担任多个投资管理职位。除了我们的董事会，Ossipow博士还任职于Immunic，Inc.，BioInvent International AB，Forx SA和Etherna Immunotherapies NV的董事会，此前曾任职于Andrew Alliance S.A.，Lifespan，Inc.，Raindance Technologies，CNX SA和Kuros Biosciences AG的董事会。Ossipow博士拥有日内瓦大学分子生物学博士学位。
- Vincent Ossipow, has served as a member of our board of directors since June 2014. Dr. Ossipow has been a partner at Omega Funds. Dr. Ossipow has also served as the Chief Scientific Officer of Omega Alpha SPAC. Prior to that, Dr. Ossipow held various investment management positions at Sectoral Asset Management and Pictet Bank. In addition to our board of directors, Dr. Ossipow serves on the board of directors of Immunic, Inc., BioInvent International AB, FoRx SA, SwissThera SA, and eTheRNA immunotherapies NV, and previously served on the board of directors of Andrew Alliance S.A., Lifespan, Inc., Raindance Technologies, CNx SA and Kuros Biosciences AG. Dr. Ossipow holds a Ph.D. in molecular biology from the University of Geneva.